肾康注射液联合前列地尔治疗糖尿病肾病疗效的评价  

Effect of Alprostadil Injection Combined with Shenkang Injection on Diabetic Nephropathy

作　　者：梅冬冬[1] 李慧敏[1] 彭月萍[1] 李辉[1] 

机构地区：[1]阜阳市人民医院肾内科,安徽阜阳236000

出　　处：《中国医学装备》2014年第B12期234-234,共1页China Medical Equipment

摘　　要：目的:探讨肾康注射液与前列地尔(曼新妥)联合应用治疗糖尿病肾病(DN)的疗效方法:随机将60例DN患者分为三组:A组肾康注射液组(20例)、B组前列地尔组(20例)和C组肾康注射液列地尔联合治疗组(20例),A组0.9%氯化钠溶液250ml+肾康注射液60ml,B组0.9%氯化钠溶液100ml+前列地尔10μg,C组肾康注射液与前列地尔联合应用,三组均1次/d,连用14 d。结果:治疗后三组患者的BUN、Cr、24 h尿蛋白、TC、TG的检测值均低于治疗前,C组患者各项指标显著低于治疗A、B组(P<0.05或P<0.01)。结论:肾康注射液及前列地尔注射液均可改善糖尿病肾病的临床指标,且两者联合使用效果更为明显。Objective： To observe the effect of Alprostadil injection combined with Shenkang injection in the treatment of diabetic nephropathy. Methods： 60 patients with diabetic nephropathy were randomly divided into Alprostadil group（20 case） Shenkang group（20 cases） and combined treatment group（20 eases）. The A group was given Shenkang injection 60ml and The B group was given Alprostadil injection（101xg/day）, The combined treatment group was given Alprostadil injection（ 10μg,once/day） and Shenkang injection （60ml,once/day）. The course of treatment was two weeks. Results： The levels ofTC, TG, Cr, BUN, 24- hour urine protein in the three groups showed significantly turn better than before （p〈0.05）, patients in the combined treatment have the best performance in three group. （p〈0.05） Conclusion： Combine treatment of Alprostadil injection and Shenkang injection have strong effective in the treatment of diabetic nephropathy.

关 键 词：肾康注射液 前列地尔 糖尿病肾病 

分 类 号：R587.24[医药卫生—内分泌]